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CD8
þ T cells are essential for host defense to intracellular bacterial pathogens such as Mycobacterium tuberculosis
(Mtb), Salmonella species, and Listeria monocytogenes, yet the repertoire and dominance pattern of human CD8
antigens for these pathogens remains poorly characterized. Tuberculosis (TB), the disease caused by Mtb infection,
remains one of the leading causes of infectious morbidity and mortality worldwide and is the most frequent
opportunistic infection in individuals with HIV/AIDS. Therefore, we undertook this study to define immunodominant
CD8 Mtb antigens. First, using IFN-c ELISPOT and synthetic peptide arrays as a source of antigen, we measured ex vivo
frequencies of CD8
þ T cells recognizing known immunodominant CD4
þ T cell antigens in persons with latent
tuberculosis infection. In addition, limiting dilution was used to generate panels of Mtb-specific T cell clones. Using the
peptide arrays, we identified the antigenic specificity of the majority of T cell clones, defining several new epitopes. In
all cases, peptide representing the minimal epitope bound to the major histocompatibility complex (MHC)-restricting
allele with high affinity, and in all but one case the restricting allele was an HLA-B allele. Furthermore, individuals from
whom the T cell clone was isolated harbored high ex vivo frequency CD8
þ T cell responses specific for the epitope, and
in individuals tested, the epitope represented the single immunodominant response within the CD8 antigen. We
conclude that Mtb-specific CD8
þ T cells are found in high frequency in infected individuals and are restricted
predominantly by HLA-B alleles, and that synthetic peptide arrays can be used to define epitope specificities without
prior bias as to MHC binding affinity. These findings provide an improved understanding of immunodominance in
humans and may contribute to a development of an effective TB vaccine and improved immunodiagnostics.
Citation: Lewinsohn DA, Winata E, Swarbrick GM Tanner KE, Cook MS, et al. (2007) Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS
Pathog 3(9): e127. doi: 10.1371/journal.ppat.0030127
Introduction
Infection with Mycobacterium tuberculosis (Mtb) remains an
important cause of infectious disease, morbidity, and mortal-
ity worldwide [1] and has emerged as a major opportunistic
infection in individuals with HIV/AIDS [2]. Control of
infection with Mtb relies heavily on the cellular immune
system, that is, the interaction of lymphocytes and Mtb-
infected macrophages and dendritic cells (DCs) [3,4]. CD8
þ T
cells are associated with strong CD4
þ TH1 cell responses, and
are not only essential for effective immunity to viral
pathogens, but also for immunity to some intracellular
bacteria, such as Listeria monocytogenes and Salmonella species
[5]. Increasing experimental evidence in the mouse tuber-
culosis (TB) model has suggested a protective role for CD8
þ T
cells in the host response. For example, adoptive transfer or
in vivo depletion of CD8
þ cells showed that this subset could
confer protection against subsequent challenge [6–8]. b2-
microglobulin–deﬁcient mice, deﬁcient in expression of
major histocompatibility complex (MHC) class I, are more
susceptible to Mtb [9] and to large doses of Bacille Calmette
Gue ´rin [10] infection than their wild-type littermates. This
ﬁnding has been corroborated in CD8-deﬁcient mice [11] and
other mice deﬁcient in class I processing and presentation
[11–13]. However, mice lacking class Ia–restricted CD8
þ T
cells demonstrate more moderate susceptibility to Mtb
infection [14,15]. In humans, Mtb-speciﬁc CD8
þ T cells have
been identiﬁed in Mtb-infected individuals and include CD8
þ
T cells that are classically, MHC-Ia, restricted [16–22], and
non-classically, MHC-Ib, restricted by HLA-E [18,23], and by
CD1 [24–26]. Taken together, studies of mice and humans
support an important role for CD8
þ T cells in TB immunity.
For most infections, the repertoire of the CD8 response is
shaped by the entry of antigen into the MHC-I processing
pathway, binding of peptides and/or non-peptide antigens to
MHC-I molecules, and recognition of these structures by T
cells. Ultimately, a relatively limited subset of pathogen-
speciﬁc T cells emerge, a process that has been termed
immunodominance [27]. While substantial effort has focused
on deﬁning immunodominant CD8 antigens for important
human viral pathogens such as HIV and cytomegalovirus
(CMV), little is known about the antigens recognized by
Editor: William Bishai, Johns Hopkins School of Medicine, United States of America
Received April 25, 2007; Accepted July 12, 2007; Published September 21, 2007
This is an open-access article distributed under the terms of the Creative Commons
Public Domain declaration which stipulates that, once placed in the public domain,
this work may be freely reproduced, distributed, transmitted, modified, built upon,
or otherwise used by anyone for any lawful purpose
Abbreviations: APC, antigen-presenting cell; CMV, cytomegalovirus; DC, dendritic
cell; LCL, lymphoblastoid cell line; LTBI, latent tuberculosis infection; MHC, major
histocompatibility complex; Mtb, Mycobacterium tuberculosis; PBMC, peripheral
blood mononuclear cell; TB, tuberculosis
* To whom correspondence should be addressed. Email: lewinsod@ohsu.edu
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e127 1240human CD8
þ T cell in response to intracellular bacterial
infections. Furthermore, although a number of commonly
recognized CD4 Mtb antigens have been described [28,29]
(ESAT-6, CFP10, Ag85, etc.), surprisingly little is known about
common Mtb antigens recognized by human CD8
þ T cells.
The majority of CD8
þepitopes that have been identiﬁed were
deﬁned by testing of Mtb peptides selected for high-afﬁnity
binding to MHC class Ia molecules (HLA-A2 in most cases;
[19,20,30–34]). In almost all of these examples, however, the ex
vivo frequency of these T cells in Mtb-infected individuals is
low or undetectable, suggesting that these speciﬁcities may
not represent immunodominant responses. In contrast, in the
limited cases in which T cells have been used to deﬁne
epitopes contained in selected Mtb antigens, high ex vivo
frequencies have been demonstrated [17,35], suggesting that a
T cell–centered approach can identify immunodominant
epitopes. Moreover, CD8
þ T cell responses to some Mtb
antigens that represent good CD4 antigens (CFP10, ESAT-6,
Ag85, and Mtb39) have been detected at high frequency in
persons infected with Mtb [17–19,34]. Therefore, we used a
limited library of overlapping synthetic peptides represent-
ing several known CD4 Mtb antigens to determine the
magnitude of the CD8 response to these antigens in persons
with active TB and latent TB infection (LTBI), as well as
uninfected individuals. Furthermore, we utilized a panel of
Mtb-speciﬁc CD8
þ T cell clones to deﬁne minimal epitopes
recognized within these antigens and determined the
contribution of these novel epitopes to the ex vivo Mtb-
speciﬁc CD8 response.
Results
Definition of Immunodominant Mtb-Specific CD8
Antigens
To deﬁne immunodominant Mtb-speciﬁc CD8 antigens,
and to determine whether or not these responses result from
infection with Mtb, we have used CD8
þ Tc e l l sf r o m
uninfected donors, those with LTBI, or those actively infected
with Mtb. Responses were determined either directly ex vivo,
or using CD8
þ T cell clones obtained by limiting dilution
cloning on Mtb-infected autologous DCs [36]. As much is
known about dominant CD4 Mtb antigens, a panel of these
commonly recognized antigens was selected for further
evaluation. These were Mtb39, CFP10, Mtb8.4, Mtb9.9A,
ESAT-6, Ag85b, 19kDa, and EsxG. To avoid bias introduced
by using peptides of predicted HLA binding speciﬁcity, we
synthesized overlapping peptides (15 aa, overlap 11 aa) to
represent the proteins of interest [17].
To accurately determine the ex vivo effector cell frequen-
cies of CD8
þ T cells, linear regression analysis was used. As
shown in Figure 1, using D466 as an example, magnetic bead–
puriﬁed CD8
þ T cells were tested against peptide-pulsed DCs
over a range of CD8
þ T cell numbers in an IFN-c ELISPOT
assay. A positive assay was determined as described below and
if positive, the antigen-speciﬁc frequency was determined
using linear regression.
Uninfected individuals (n ¼ 14), those with LTBI (n ¼ 20),
and those with active TB (n ¼ 12) were evaluated for CD8
responses to a panel of Mtb CD4
þT cell antigens, as well as to
Figure 1. Determination of Human Effector Cell Frequencies Ex Vivo Using the IFN-c ELISPOT Assay
Magnetic bead–purified CD8
þ T cells from a single donor (D466) were cultured with DCs (20,000/well) either infected with Mtb (H37Rv, multiplicity of
infection ¼ 50) or pulsed with peptide pool representing CFP10 (5 lg/ml each peptide; 15-mer overlap by 11 aa) in an IFN-c ELISPOT assay. Each
responding T cell population was tested in duplicate at four different cell concentrations. To determine the effector cell frequency of antigen-specific T
cells, the average number of spot forming units per well for each duplicate was plotted against the number of responder cells per well. Linear
regression analysis was used to determine the slope of the line, which represents the frequency of antigen-specific T cells. The assay was considered
positive, reflecting the presence of a primed T cell response, if the binomial probability for the number of spots was significantly different by
experimental and control assays, i.e., if the experimental line is statistically significantly different from the control line. The frequency of Mtb-specific and
CFP10-specific T cells demonstrated in this figure was 1/307 and 1/1676, respectively.
doi:10.1371/journal.ppat.0030127.g001
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Author Summary
CD8
þ T cells are essential for host defense to intracellular bacterial
pathogens such as Mycobacterium tuberculosis (Mtb), Salmonella
species, and Listeria monocytogenes, yet little is known about the
antigens recognized by human CD8
þ T cells in response to
tuberculosis (TB). TB, the disease caused by Mtb infection, remains
one of the leading causes of illness and death worldwide and is a
frequent complicating infection in individuals with HIV/AIDS.
Therefore, we undertook this study to define commonly recognized
CD8 Mtb antigens. First, we measured the frequencies of CD8
þ T
cells recognizing Mtb antigens known to be recognized by CD4
þ T
cell antigens in persons infected with Mtb. In addition, we identified
the Mtb antigen and epitope recognized by several CD8
þ T cell
clones isolated from infected individuals. The epitope was presented
to the T cell clones by an HLA-B allele in all but one case. We
conclude that Mtb-specific CD8
þ T cells are found in high frequency
in infected individuals and are restricted predominantly by HLA-B
alleles. These findings provide an improved understanding of how
the human immune system recognizes intracellular pathogens and
may contribute to the development of an effective TB vaccine and
improved immunodiagnostics.Mtb-infected DCs. All individuals tested had robust CD8
þ T
cell responses to Mtb-infected DCs and were of greater
magnitude in individuals with active TB than in those with
LTBI (p ¼ 0.01; Figure 2; Table 1). However, CD8
þ T cell
responses to the panel of Mtb antigens were found almost
exclusively in those infected with Mtb in that statistically
signiﬁcant differences between uninfected and Mtb-infected
individuals were noted for seven of ten antigens for both the
magnitude of the response (Figure 2) and the proportion of
positive assays (Table 1). However, differences in CD8
þ T cell
responses between individuals with active TB and LTBI were
not statistically different. While strong CD8
þ T cell responses
were observed against many of the antigens tested, it is
equally notable that several individuals with strong Mtb-
directed CD8
þ T cell responses did not have demonstrable
responses to many of the antigens tested (unpublished data).
Definition of the Minimal Epitope Recognized by Mtb-
Specific CD8þ T Cell Clones
These ex vivo frequency data demonstrated the presence of
high-frequency responses to a number of known Mtb
antigens, but did not shed light on the restricting allele,
minimal epitope, or dominance hierarchy within the gene of
interest. To address this question, we performed limiting
dilution cloning of human CD8
þ T cells using Mtb-infected
DCs [36], and generated panels of both classically and non-
classically HLA-restricted CD8
þ T cell clones. Using peptide
pools representing known CD4 antigens, the antigenic
speciﬁcity of the HLA-Ia-restricted clones was deﬁned in
more than half of the clones (Table 2). This approach is
demonstrated in detail for a single representative clone, D466
D6, derived from an individual with active TB. As shown in
Figure 3A, testing the clone against autologous DCs pulsed
with a panel of peptide pools unambiguously deﬁned the
antigenic speciﬁcity as CFP10. The clone was then tested
against each of the 15-mer peptides that comprise the CFP10
pool, revealing that the epitope was contained within
CFP101–15 (Figure 3B). Each possible 8-aa, 9-aa, 10-aa, and
11-aa peptide was then synthesized and tested for reactivity,
revealing antigenic activity between aa 2–11 (Figure 3C).
Similarly, each clone was tested against lymphoblastoid cell
lines (LCLs) sharing at least one HLA type with the donor
(Figure 3D). Autologous LCL and IHW 9058 LCL, which share
Figure 2. High Ex vivo CD8
þ T Cell Frequencies to Mtb Antigens Are Associated with Mtb Infection
As in Figure 1, to determine ex vivo CD8
þT cell frequencies, autologous DCs either infected with Mtb (graph labeled ‘‘Mtb DC’’) or pulsed with cognate
peptide pools representing known Mtb CD4 antigens (all other graphs) were incubated with CD8
þT cells in an IFN-c ELISPOT assay. The number of spot
forming units (SFU)/250,000 cells is shown, a number which is derived from linear regression analysis of the frequency of T cells tested at concentrations
of 5310
5, 2.5310
5, 1.2310
5, and 6310
4 cells/well. Individuals without evidence for Mtb infection (‘‘normal’’); those with LTBI, and those with active
TB (‘‘active’’ defined as culture confirmed pulmonary TB) were evaluated. ‘‘Mtb Infected’’ includes both the ‘‘LTBI’’ and ‘‘active’’ groups. The number of
individuals tested for each antigen were: Mtb infection (normal, n¼11; LTBI, n¼11; active, n¼6); Mtb39 Pool A (normal, n¼14; LTBI, n¼20; active, n¼
10); Mtb39 Pool B (normal, n¼14; LTBI, n¼20; active, n¼10); CFP10 (normal, n¼14; LTBI, n¼20; active, n¼10); Mtb8.4 (normal, n¼14; LTBI, n¼20;
active, n¼10); Mtb9.9A (normal, n¼14; LTBI, n¼20; active, n¼5); ESAT-6 (normal, n¼14; LTBI, n¼20; active, n¼5); Ag85 Pool A (normal, n¼14; LTBI, n
¼17; active, n¼5); Ag85 Pool B (normal, n¼14; LTBI, n¼17; active, n¼5); 19kDa (normal, n¼12; LTBI, n¼17; active, n¼5); and EsxG (normal, n¼14;
LTBI, n¼17; active, n¼5). p-Values are noted where statistically significant differences between groups are noted (p¼,0.05; Wilcoxon/Kruskal–Wallis).
doi:10.1371/journal.ppat.0030127.g002
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identifying both B4501 and C1601 as possible restricting
alleles. However, C1601
þ D433 LCL did not present the
epitope, eliminating C1601 as a candidate-restricting allele.
Therefore, D466 D6 was restricted by HLA-B4501. As
demonstrated in Figure 4, by testing each plausible epitope
over a broad range of concentrations, the minimal epitope
was deﬁned as CFP102–12 for D466 D6. Experimental data
supporting the assignment of the minimal epitope is
provided for each clone in Figure 5, and a summary of the
antigenic speciﬁcity, minimal epitope, and HLA-restricting
allele is presented in Table 3. Unexpectedly, all but one of the
T cell clones were restricted by HLA-B alleles. Furthermore, a
minority of those observed were 9 aa in length.
Immunodominance of MTb CD8 Epitopes in Infected
Individuals
Because each of the individual CD8
þ T cell clones was
derived based on growth in the presence of Mtb- infected
DCs, we sought to determine whether or not the antigen and
epitopes identiﬁed reﬂected immunodominant epitopes ex
vivo. Two independent approaches were pursued, the ﬁrst to
determine if the response was present at high frequency, and
the second to determine what proportion of the total
response to the antigen was constituted by the epitope. To
determine the ex vivo effector cell frequency, as described in
Figure 1, each epitope was tested using autologous DCs and
magnetic bead–puriﬁed CD8
þ T cells derived from the donor
from whom the T cell clones was isolated. A summary of the ex
vivo epitope-speciﬁc effector cell frequencies is presented in
Table 3. For comparison, effector cell frequencies using
autologous DCs infected with Mtb as the antigen-presenting
cells (APCs) are shown as well. For 11 CD8
þ T cell clones
recognizing distinct epitopes, the epitope-speciﬁc frequency
exceeded 50% of the total Mtb-speciﬁc CD8
þ T cell response.
For six of these clones, the epitope-speciﬁc frequency actually
exceeded the total frequency of Mtb-speciﬁc CD8
þ T cells.
Conversely, for two clones, the epitope-speciﬁc T cell
frequency constituted the minority of the total Mtb-speciﬁc
CD8
þ T cell response. Thus, overall, the epitopes reﬂected
high-frequency responses, and could be considered a re-
sponse that has been primed by exposure to Mtb. Notably, T
cell clones isolated from four donors recognized CFP10. To
determine if the epitopes deﬁned reﬂected a substantial
Table 1. CD8
þ T Cell Responses to Known TB Antigens
Antigen Mtb-Infected Individuals
Number Positive
a / Number Tested (%)
Mtb-Uninfected Individuals
NumberPositive
a / Number Tested (%)
p-Value (2-Tail Fisher’s)
Mtb DC 17/17 (100) 11/11 (100)
Mtb39 Pool A 13/30 (43) 0/14 (0) 0.003
Mtb39 Pool B 10/30 (33) 0/14 (0) 0.01
CFP10 14/30 (47) 1/14 (7) 0.02
Mtb8.4 13/30 (43) 0/14 (0) 0.003
Mtb9.9A 10/25 (40) 1/14 (7) 0.06
ESAT 6 12/25 (48) 0/14 (0) 0.003
Ag85b Pool A 5/22 (23) 1/14 (7) 0.37
Ag85b Pool B 4/22 (18) 0/14 (0) 0.14
19kd 6/22 (27) 1/12 (8) 0.38
EsxG 9/22 (41) 0/14 (0) 0.006
aPositive assay defined in text.
doi:10.1371/journal.ppat.0030127.t001
Table 2. Many CD8
þ T Cell Clones Recognize Known CD4 Antigens
Donor TB Status HLA-Ia Clones (Number)
a Antigen Identified (Number)
b Number Distinct Antigens
c Number Distinct Epitopes
d
D431 Active TB 1 0 0 0
D432 Active TB 14 4 2 2
D466 Active TB 11 10 1 2
D571 Active TB 7 7 1 1
D480 Active TB 6 6 1 1
D481 Active TB 11 11 1 1
D426 LTBI 1 0 0 0
D443 LTBI 1 1 1 1
D454 LTBI 2 2 2 2
D504 LTBI 7 1 1 1
Totals 61 42 10 11
aNumber of clones derived from donor.
bNumber of clones for which cognate antigen was identified.
cTotal number of distinct antigens identified from the clone set.
dTotal number of distinct epitopes identified from the clone set.
doi:10.1371/journal.ppat.0030127.t002
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magnetic bead–puriﬁed CD8
þ T cells from three donors with
sufﬁcient available peripheral blood mononuclear cells
(PBMCs) were tested for reactivity to each individual 15-
mer peptide, the peptide pool, and peptide representing the
minimal epitope. As is demonstrated in Figure 6, the ex vivo
frequencies to the minimal epitope, 15-mer peptide(s)
containing the minimal epitope, and peptide pool were
remarkably concordant. These data, then, suggest that for
each donor a dominance hierarchy has been clearly estab-
lished, and was reﬂected in the original clones. Finally, as is
noted in Table 3, daughter clones of identical speciﬁcity were
frequently identiﬁed, a result that would be predicted based
on an immundominance hierarchy. TCR V beta staining was
used to conﬁrm the clonal relationship between daughter
clones. Interestingly, in two cases, the identical minimal
epitope and HLA restriction was represented by two distinct
clones (Table 3).
HLA Binding Affinity to CD8
þ T Cell Epitopes
Because much work on human CD8
þT cell responses to Mtb
has relied upon the use of HLA prediction algorithms, as each
epitope was deﬁned we asked whether or not the epitopes
would have been predicted by these approaches. Given the
prevalence of HLA-B alleles and 10-mer and 11-mer epitopes,
it is perhaps not surprising that many of these epitopes were
not ranked strongly (unpublished data). This left open the
possibility that either HLA binding was indeed not predictive
of antigenicity, or simply highlighted the limitations of those
algorithms at the time they were used. To address this
question experimentally, the IC50 for each peptide that had
been synthesized in the course of deﬁnition of the minimal
epitope was determined against a panel of human HLA
molecules (Table S1). Shown in Table 3 is the IC50 for the
minimal epitope with the cognate restricting allele. These data
demonstrate that the T cell epitopes bound avidly to HLA,
and show a high degree of concordance between the T cell
epitope data and HLA binding data (Figure 5; Table S1).
Discussion
Although the complete repertoire of CD8
þ T cell responses
in Mtb remains incompletely characterized, the following
conclusions can be drawn. First, CD8
þ T cell responses are
Figure 3. Definition of Antigenic Specificity and HLA Restriction:
Characterization of T Cell Clone D466 D6
(A–C) To identify the antigen and minimal epitope recognized by T cell
clone D466 D6, T cells (5,000 cells/well) were incubated with autologous
LCL (20,000/well) and antigen (5 lg/ml). Negative controls (media, no
antigen) and positive controls (phytohemagglutanin [PHA], final, 10 lg/
ml) are shown for each assay. IFN-c was assessed by ELISPOT after 18 h of
co-culture. Pictures of ELISPOT wells are shown.
(A) Antigens consisted of peptide pools representing known CD4 Mtb
antigens, made up of 15-aa peptides overlapping by 11 aa.
(B) Antigens consisted of individual 15-aa CFP10 peptides that together
constitute the peptide pool.
(C) Antigens consisted of individual nested peptides within CFP101–15 (10
aa, 9 aa, or 8 aa), used to further map the epitope.
(D) The restricting allele was identified using LCLs (20,000/well) that were
either autologous or expressing HLA alleles matching D466 at one or two
alleles (shown in bold font), pulsed with CFP102–10 (5 lg/ml) as APC.
Autologous LCLs without peptide (control) are also shown. After 2 h,
cells were washed and incubated with T cells (500 cells/well) in an IFN- c
ELISPOT assay. Pictures of ELISPOT wells are shown.
doi:10.1371/journal.ppat.0030127.g003
Figure 4. Confirmation of Minimal Epitope Mapping of D466 D6
To confirm the minimal epitope, autologous LCLs (20,000/well) were
pulsed with peptide at the concentration indicated and co-cultured with
T cells (1,000 cells/well). IFN-c was assessed by ELISPOT after 18 h co-
culture. Each point represents the mean of duplicate determinations.
doi:10.1371/journal.ppat.0030127.g004
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comparable to that seen following many common viral
infections such as vaccinia, inﬂuenza, and CMV [37,38]. This
conclusion is based both on the pooled peptide experiments
described above, and on the observation that when deﬁned,
dominant epitopes are present at high ex vivo frequencies.
Conversely, we have not observed high-frequency responses
to CD4
þT cell antigens in those without evidence of infection
Figure 5. Summary of Minimal Epitope Mapping Data
To determine the minimal epitope, autologous LCLs (20,000/well) were pulsed with peptide at the concentration indicated and co-cultured with T cells
(1,000 cells/well). IFN-c was assessed by ELISPOT after 18 h co-culture. Each point represents the mean of duplicate determinations.
doi:10.1371/journal.ppat.0030127.g005
Table 3. Summary of CD8þ T Cell Epitopes Identified
Donor Mtb-Specific
T Cells
a
Clone
b Gene
c HLA-Restricting
Allele
Epitope
Location
Epitope
Sequence
Epitope-Specific
T Cells
a
MHC Binding
Affinity (IC50 nm)
V Beta
Region
160 61
d D160 1–1B
d (0) CFP10 B44 2–11 AEMKTDAATL 360 38
160 61
d D160 1–6F
d (0) CFP10 B14 85–94 RADEEQQQAL 120 NA
432 216 D432 H12 (1) CFP10 B3514 49–58 TAAQAAVVRF 258 2,011
e 5.3
466 473 D466 A10 (9) CFP10 B4501 2–9 AEMKTDAA 2,458 48 IND
466 814 D466 D6 (0) CFP10 B4501 2–12 AEMKTDAATLA 1,993
f 6.2 22
481 405 D481 C10 (9) CFP10 B1502 75–83 NIRQAGVQY 1,715 14
g 9
481 405 D481 C11 (0) CFP10 B1502 75–83 NIRQAGVQY 1,715 14
g 13.6
480 598 D480 F6 (5) CFP10 B0801 3–11 EMKTDAATL 387 79 13.1
571 49 D571 B12 (2) CFP10 B4402 2–11 AEMKTDAATL 31 38 IND
571 49 D571 E9 (3) CFP10 B4402 2–11 AEMKTDAATL 31 38 14
504 126 D504 E4 (0) EsxG A0201 3–11 LLDAHIPQL 72 0.39 8
454 138 D454 B10 (0) EsxG B0801 53–61 AAHARFVAA 88 0.22 IND
454 138 D454 H1–2 (0) Mtb8.4 B1501 33–43 AVINTTCNYGQ 24 10 7.1
432 216 D432 A3 (1) Mtb8.4 B3514 61–69 ASPVAQSYL 210 127
e 14
443 53 D443 H9 (0) Ag85B B4102 144–153 ELPQWLSANR ,10 NA 22
aIFN-c spot forming units per 250,000 CD8
þ T cells.
bNumber of sister clones is in parentheses.
cTubercuList accession numbers are CFP10 (Rv3874) and EsxG (Rv0287).
dPublished previously in [17].
eMeasured binding affinity to B3501 is shown.
fGiven that D466A10 also recognized this longer peptide, this ex vivo frequency may reflect the response to the shorter peptide CFP102–9 as well.
gMeasured binding affinity to B1501 is shown.
IND, indeterminate; NA, not available; TBD, to be done.
doi:10.1371/journal.ppat.0030127.t003
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that these responses reﬂect an adaptively acquired response
to infection with Mtb, rather than an innate response. By
contrast, CD8
þ T cell responses to Mtb-infected DCs were
equivalent in infected and uninfected individuals. Using
limiting dilution analysis, we have studied the proportions of
Ia- versus Ib- restricted CD8
þ T cells in Mtb-infected
compared to uninfected individuals and have noted that Ib-
restricted CD8
þ T cell responses predominate in uninfected
individuals (D. Lewinsohn, unpublished data). Therefore, we
speculate that the response detected to Mtb-infected DCs in
uninfected individuals may reﬂect chieﬂy a Ib-restricted
response. While we did not observe an association of
responses to speciﬁc antigens with disease status, a larger
study might reveal more subtle differences.
All but one of the epitopes that have been mapped to date
are restricted by HLA-B molecules. The reasons for this
possible skewing are not yet clear. It is a formal possibility
that the cloning methods we used biased isolation of HLA-B-
over HLA-A-restricted T cell clones. However, using identical
cloning methodology, we have isolated T cell clones speciﬁc
for vaccinia, CMV, and inﬂuenza that did not display a
preference for HLA-B restriction (D. Lewinsohn, unpub-
lished data). Furthermore, in all three cases where we tested ex
vivo the entire set of peptides representing CFP10, the entire
response mapped to the HLA-B-restricted epitope (Figure 6).
Therefore, we speculate that Mtb antigens may preferentially
bind to HLA-B molecules, that Mtb preferentially interferes
with HLA-A processing and presentation, that infection with
Mtb leads to selective upregulation of HLA-B, or that HLA-B
is preferentially delivered to the Mtb phagosome. Nonethe-
less, these data are consistent with those reported by Kiepiela
et al. [39], in which HIV-speciﬁc T cell responses were found
to be 2.5-fold more likely to be HLA-B- than HLA-A-
restricted, and observed that viral load was more closely
linked to HLA-B than HLA-A alleles. Human infection with
mycobacteria has been demonstrated in pre-urban Egypt [40]
and in pre-Columbian Peru [41], observations consistent with
the hypothesis that mycobacterial infection has driven the
diversity and peptide-binding repertoire of the HLA-B locus.
Furthermore, our data is consistent with the hypothesis that
the diversity of HLA-B alleles is related to the containment of
both viral and bacterial pathogens. Hence, delineation of
immunodominant epitopes and antigens within the context
of important human pathogens will likely require careful
evaluation of those epitopes presented by HLA-B.
While the immune response within an individual to a given
antigen is narrowly focused, dominant epitopes that would be
useful for population-based analysis have yet to be deﬁned.
This conclusion is based on the fact that few of the HLA-A2
e p i t o p e sd e s c r i b e dt od a t eh a v ep r o v e dt ob ew i d e l y
recognized, and, most importantly, on the observation that
a wide variety of HLA alleles appear to be used in the
recognition of Mtb antigens. The antigen CFP10 is an
excellent case in point. As is demonstrated in Table 3, T cell
clones have been used to deﬁne high-frequency epitopes
restricted by a variety of HLA alleles. While the N-terminal 15
aa could reasonably be considered immunogenic, in all but
one case (CFP102–11; HLA-B44) the minimal epitope deﬁned
has been unique to the individual from whom the T cells were
derived.
By using a T cell–driven approach to epitope identiﬁcation,
it is possible to deﬁne dominant epitopes in humans infected
with Mtb. While it is striking that for several of the T cell
clones the ex vivo frequency of epitope-speciﬁc T cells was
equal to or exceeded the total ex vivo frequency of Mtb-
Figure 6. Profiling of Immunodominance Pattern for CFP10
To determine the effector cell frequencies, autologous DCs (20,000/well)
were pulsed either with each individual 15-mer peptide (5 lg/ml), the
peptide pool (PP; 5 lg/each peptide), or the minimal epitope (ME)
determined from T cell clones derived from each donor (D466:CFP102–11;
D480:CFP103–11; D481:CFP1075–83;5lg/ml), and tested against 250,000
magnetic bead–purified CD8
þ T cells. IFN-c release was assessed by
ELISPOT after 18 h of co-culture. Each point represents the mean of
duplicate determinations.
doi:10.1371/journal.ppat.0030127.g006
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loaded DCs to determine T cell frequency likely over-
represents the proportion of the total Mtb-speciﬁc CD8
þ T
cell responses. Possible reasons are that Mtb infection is likely
to produce relatively less cognate peptide compared to
peptide loading, and that Mtb infection could possibly
interfere with class I processing and presentation. Although
the current observations are limited to a small panel of
known CD4 antigens, current work is underway to perform a
genome-wide survey of dominant CD8 antigens in Mtb.
Deﬁnition of this panel will likely prove useful in the further
study of the natural history of infection with Mtb and in the
design of novel vaccines and diagnostics.
In TB, evaluation of epitopes based strictly on HLA binding
algorithms has focused on HLA-A2, and has often failed to
deﬁne dominant epitopes. Our observation that many of the
epitopes are HLA-B restricted, and often longer than 9 aa, for
which these algorithms are less robust, may help explain these
ﬁndings. However, when evaluated experimentally, all of the
minimal epitopes exhibit high-afﬁnity binding to the cog-
nate-restricting allele. In this regard, substantial progress in
HLA prediction algorithms is evident [42,43], and could
facilitate more efﬁcient identiﬁcation of dominant epitopes.
Here, more information with regard to longer peptides will
be of beneﬁt. Finally, we speculate that these caveats are likely
to apply to other intracellular pathogens as well.
One limitation to current knowledge is that the responses
in humans have been made at a single time point. In this
regard, a feature of Mtb is the chronic exposure to antigen
that may persist for many years. How this chronic infection
inﬂuences the shaping of the immune response and domi-
nance repertoire is an important question that remains
unresolved. The advent of new reagents for immunologic
studies in the mouse model [44] will likely be useful in this
regard. For example, chronic antigenic exposure seems likely
to alter the afﬁnity of the T cell response over time.
Furthermore, it is possible that such long-term infection
might lead to clonal exhaustion or dysfunction as has been
described for chronic viral infection [38]. Finally, given the
very high-frequency responses that we and others have
observed to Mtb-infected DCs and to single antigens, it
appears that the immune response to Mtb occupies a sizable
fraction of the host’s immunological activity, similar to that
previously observed for infection with CMV [45]. If so, then
this may have important implications for the aging immune
system, and potentially for the requirements for the long-
term containment of intracellular infection. For example, it is
possible that threshold Mtb-speciﬁc CD8 frequencies are
necessary for the maintenance of a state of chronic
persistence. Conversely, the substantial immunological effort
directed at Mtb may limit the host’s ability to effectively
combat novel infections. As a result, this static picture leaves
open important questions as to the evolution of the Mtb-
speciﬁc responses, and its relationship with chronic infection
with Mtb.
It seems likely that Mtb has evolved potent mechanisms to
modulate the immune response. At present, speciﬁc mecha-
nisms for MHC-I immune modulation have not been
described. However, it appears that TLR II stimulation via
the Mtb-derived 19-kDa lipoprotein can modulate both
MHC-I and MHC-II antigen processing, and can interfere
with IFN-c signaling [46–49]. Further work on the T cell
subsets important in Mtb, including the immunodominant
epitopes, will extend our understanding of the immunology
of TB and potentially contribute to the development of a
vaccine against this major killer.
How the Mtb-speciﬁc CD8
þ T cell response ﬁts into the
natural history of infection with Mtb remains poorly
characterized. For example, the ontogeny of the CD8
þ T cell
response relative to infection with Mtb remains unknown, as
does the relationship of CD8
þ T cell frequencies with regard
to bacterial burden. However, by deﬁning commonly recog-
nized CD8
þ T cell antigens and epitopes, it will become
increasingly possible to employ direct ex vivo analysis to more
precisely deﬁne Mtb-speciﬁc T cell responses in various
subject groups of particular interest.
Materials and Methods
Study participants. Study participants, protocols, and consent
forms were approved by the Oregon Health and Science University
institutional review board. Informed consent was obtained from all
participants. Uninfected individuals and individuals with LTBI were
recruited from employees at Oregon Health and Science University
as previously described [36]. Uninfected individuals were deﬁned as
healthy individuals with a negative tuberculin skin test and no known
risk factors for infection with Mtb. Individuals with LTBI were
deﬁned as healthy persons with a positive tuberculin skin test and no
symptoms and signs of active TB. Individuals with active TB were
recruited via institutional review board–approved advertisement and
were self-referred from the Multnomah County TB Clinic, Portland,
Oregon, United States, or from the Washington County TB Clinic,
Hillsboro, Oregon, United States. In all active TB cases, pulmonary
TB was diagnosed by the TB Controller of these counties and
conﬁrmed by positive sputum culture for Mtb. PBMCs were isolated
from whole blood obtained by venipuncture or apheresis.
Media and reagents. Culture medium consisted of RPMI 1640
supplemented with 10% fetal bovine sera (BioWhittaker, http://www.
cambrex.com/), 5 3 10
 5 M 2 ME (Sigma-Aldrich, http://www.
sigmaaldrich.com/), and 2 mM glutamine (GIBCO BRL, http://www.
invitrogen.com/). For the growth and assay of Mtb-reactive T cell
clones, RPMI 1640 was supplemented with 10% human serum. Mtb
strain H37Rv was obtained from the American Type Culture
Collection (http://www.atcc.org/) and prepared as previously de-
scribed [36]. Peptides were synthesized by Genemed Synthesis
(http://www.genemedsyn.com/). Synthetic peptide pools consisted of
15 mers overlapping by 11 aa, representing Mtb proteins demon-
strated to be potent CD4 antigens. Peptide pools representing CFP10
[50,51], ESAT-6 [52], Mtb39a (two pools, A & B) [53], Mtb8.4 [54], Mtb
9.9A [16], EsxG [55,56], 19kDa antigen [57], and antigen 85b (two
pools, A & B) [58] were synthesized. Peptides were resuspended in
DMSO, and up to 50 peptides were combined into one pool such that
each peptide in the pool was at a concentration of 1 mg/ml. Peptide
pools were stored at  80 8C.
Cell lines and T cell clones. EBV-transformed B cell lines, LCLs,
were either generated in our laboratory using supernatants from
the cell line 9B5–8 (American Type Culture Collection) or obtained
from the National Marrow Donor Program (http://www.marrow.org/).
LCLs were maintained by continuous passage as previously
described [18]. Mtb-speciﬁc T cell clones were isolated from
individuals with LTBI or active TB, using Mtb-infected DCs as
APCs and limiting dilution cloning methodology as previously
described [36]. Brieﬂy, CD8
þT cells were isolated from PBMCs using
negative selection using CD4 antibody-coated beads and then
positive selection using CD8 antibody-coated magnetic beads per
the manufacturer’s instructions (Miltenyi Biotec, http://www.
miltenyibiotec.com/) or via ﬂow cytometry. In this case, CD4-PE
(BD Biosciences, catalog #555347; http://www.bdbiosciences.com/)
negative and CD8-APC (BD Biosciences, catalog #555369) positive
cells (purity .99%) were sorted on a Becton Dickinson LSR II (http://
www.bd.com/). T cells were seeded at various concentrations in the
presence of a 1 3 10
5–irradiated autologous Mtb-infected DC,
generated as described below, and rIL-2 (5 ng/ml) in cell culture
media consisting of 200 ll of RPMI 1640 supplemented with 10%
human sera. Wells exhibiting growth between 10–14 d were assessed
for Mtb speciﬁcity using ELISPOT and Mtb-infected DCs as a source
of APCs. T cells retaining Mtb speciﬁcity were further phenotyped
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expanded as described below. V beta usage was determined using the
IOTest Beta Mark Kit from Beckman Coulter, catalog #IM3497
(http://www.beckmancoulter.com/).
Expansion of T cell clones. To expand the CD8
þ T cell clones, a
rapid expansion protocol using anti-CD3 mAb stimulation was used
as described previously [18].
Generation and infection of peripheral blood DCs. Monocyte-
derived DCs were prepared according to a modiﬁed method of
Romani et al. [18,59]. To generate Mtb-infected DCs, cells (1 3 10
6)
were cultured overnight in the presence of Mtb at a multiplicity of
infection ¼ 50:1. We have determined that this multiplicity of
infection is optimal for detection of Mtb-speciﬁc CD8
þ T cells, as
heavy infection is required to optimize entry of antigen into the class
I processing pathway [60]. After 18 h, the cells were harvested and
resuspended in RPMI/10% human serum.
MHC binding assays. The MHC peptide binding assay utilized
measures the ability of peptide ligands to inhibit the binding of a
radiolabeled peptide to puriﬁed MHC molecules, and has been
described in detail elsewhere [61] . Brieﬂy, puriﬁed MHC molecules,
test peptides, and a radiolabeled probe peptide are incubated at
room temperature in the presence of human b2-microglobulin and a
cocktail of protease inhibitors. After a 2-d incubation, binding of the
radiolabeled peptide to the corresponding MHC class I molecule is
determined by capturing MHC/peptide complexes on W6/32 antibody
(anti-HLA A, B, and C) or B123.2 (anti-HLA B, C, and some A) coated
plates, and measuring bound cpm using a microscintillation counter.
For competition assays, the concentration of peptide yielding 50%
inhibition of the binding of the radiolabeled peptide is calculated.
Peptides are typically tested at six different concentrations covering a
100,000-fold dose range, and in three or more independent assays.
Under the conditions utilized, where [label] , [MHC] and IC50  
[MHC], the measured IC50 values are reasonable approximations of
the true Kd values.
IFN-c ELISPOT assay. The IFN-c ELISPOT assay was performed as
described previously [18]. For determination of ex vivo frequencies of
CD8
þ T cells responding to Mtb infection or Mtb antigens, CD8
þ T
cells were positively selected from PBMCs using magnetic beads
(Miltenyi Biotec) such that .97% of the cell population were CD8
þ T
cells. These CD8
þ T cells were used as a source of responder T cells
and tested in duplicate at four different cell concentrations (5 310
5,
2.5 3 10
5, 1.2 3 10
5, and 6 3 10
4 cells/well). Autologous DCs (20,000
cells/well) were used as APCs, and DCs were either infected with Mtb
or pulsed with peptide pools (5 lg/ml, ﬁnal concentration of each
peptide) and then added to the assay. For assays using T cell clones, T
cells (1,000 or 5,000 cells/well) were incubated with autologous LCL
(20,000 cells/well) in the presence or absence of antigen. Negative and
positive controls were included in each assay and consisted of wells
containing T cells and DCs either without antigen or without antigen
but with inclusion of phytohemagglutanin (PHA, 10 lg/ml; EMD
Biosciences, http://www.emdbiosciences.com/), respectively. For all
assays, responding T cells were incubated with APCs overnight.
Data analysis. To determine the ex vivo frequency of antigen-
speciﬁc T cells, the average number of spots per well for each
duplicate was plotted against the number of responder cells per well.
Linear regression analysis was used to determine the slope of the line,
which represents the frequency of antigen-speciﬁc T cells. The assay
is considered positive, i.e., reﬂecting the presence of a primed T cell
response, if the binomial probability [62] for the number of spots is
signiﬁcantly different by experimental and control assays, i.e., if the
experimental line is statistically signiﬁcantly different from the
control line. To determine differences in ex vivo T cell frequencies
between groups, Wilcoxon/Kruskal–Wallis analysis was used.
Online supplemental material. Ex vivo T cell frequencies and MHC
binding assays were performed exactly as described above.
Supporting Information
Table S1. IC50 (nM) of Peptide Binding to HLA
Found at doi:10.1371/journal.ppat.0030127.st001 (87 KB PDF).
Accession Numbers
The accession numbers from TubercuList (http://genolist.pasteur.fr/
TubercuList/) for Mtb proteins discussed in the manuscript are as
follows: 19kd (Rv3763); Ag85B (Rv1886c), CFP10 (Rv3874); ESAT 6
(Rv3875); EsxG (Rv0287), Mtb8.4 (Rv1174c); Mtb9.9A (Rv1793); Mtb39
(Rv1196).
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